The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and is expected to witness a decline in its revenue to USD 4.34 billion by 2025, shrinking at a CAGR of 2.9%. Patent expiry of blockbuster drugs prescribed for the treatment of acid reflux disorders is majorly attributable for the downfall of this market.
Rife with patent litigations and strong clinical pipelines, the market landscape continues to experience substantial changes. Proton pump inhibitors and histamine H2 receptor antagonists hold prominence in the current market scenario.
U.S. GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Upon loss of patent protection of previously dominant branded drugs, low-priced generic molecules can consume up to 90% sales of branded molecules. Growing number of companies worldwide increasingly being subjected to price scrutiny coupled with shift in government focus on promoting consumer accessibility will engender further drug price reductions. Although expiry of major patents has affected the market turnover, the demand for acid-reducing drugs, owing to the rising incidence of heartburn across the globe, is expected to escalate in the coming years.
While GERD devices serve as an alternative approach to managing heartburn, these devices have struggled owing to their low success rates and failed clinical trials. Hence, limited acceptance of GERD management devices have contributed to the increasing demand for acid neutralizing drugs as the major therapy approach.
However, GERD devices for minimally invasive procedures to address underlying anatomical defects are steadily gaining traction with growing supportive clinical evidence for devices to perform procedures, such as transoral fundoplication, which prevent reflux of acid and non-acid contents altogether. To further reinforce its adoption in the U.S., a new CPT code (43210) was established to facilitate the reimbursement process in 2016.
Antacids held the dominant market share in the year 2016 and are to retain their top position throughout the forecast period. Antacids are preferred as first-line therapy for mild and infrequent symptoms as they neutralize gastric acid secretions immediately. Convenient over-the-counter availability of antacids in various forms such as tablets, powders, and syrups is responsible for their excessive adoption. In addition, the American Hospital Formulary, among other countries, enlists over 120 antacid preparations to advocate their use.
PPIs accounted for the second largest segment in 2016 as they are the most commonly prescribed medication type for heartburn. Inflow of generics following the loss of exclusivity of popular drugs, including Nexium and Prilosec, has affected the sales of branded PPIs. A further decline is looming large with the awaited expiration of other patent-protected therapeutics, such as Dexilant.
North America was identified as the largest regional segment in terms of market share for GERD therapeutics in the year 2016. In the U.S., every year, more than 80 million people experience GERD symptoms, of which, 25 million people suffer from heartburn or acid reflux daily and 60 million people on a monthly basis.
In addition, the number of outpatient clinic visits related to GERD in the U.S. has been increasing in the last few years stemming from the fact that the geriatric population is more prone to developing heartburn and acid reflux. Nearly 18% of the American population will be aged 65 and more by 2025.
On the other hand, the Asia Pacific region is projected to showcase the fastest growth rate over the forecast period. The rising geriatric population and lifestyle & dietary risk factors such as obesity & high fat diet, respectively, is expected to drive the market growth in this region. In developing countries, such as India and China, the trend of self treatment is rapidly growing due to the availability and affordability of OTC antacids.
Global GERD therapeutics market, by Region, 2016 (USD Million)
A highly competitive generics-driven market is creating downward pressure on drug prices with lowered retail sales, which will engender stagnant growth in the coming years. The competition between the companies manufacturing these drugs ranges from medium to high. AstraZeneca PLC; Eisai Co., Ltd.; GlaxoSmithKline PLC; Takeda Pharmaceutical Co., Ltd.; and Johnson & Johnson account for the top players in the market. Moreover, Daewoong Pharmaceutical Co., Ltd.; Ironwood Pharmaceuticals, Inc.; SRS Pharmaceuticals Pvt. Ltd.; and SFJ Pharmaceuticals Group are some of the emerging companies in this industry.
Amongst others in this space, Ironwood Pharmaceuticals, Inc. and RaQualia Pharma, Inc. are focusing on developing new generic molecules involving existing and novel drug mechanisms as part of their strategy to invade the market. This space is also marked by numerous generic players vying to capture a larger market share through copycat versions to replace the expired blockbuster drugs.
Report Attribute |
Details |
Market size value in 2020 |
USD 4.6 billion |
Revenue forecast in 2025 |
USD 3.2 billion |
Growth Rate |
CAGR of 2.3% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD Million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Drug type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa |
Key companies profiled |
AstraZeneca PLC; Eisai Co., Ltd.; GlaxoSmithKline PLC; Takeda Pharmaceutical Co., Ltd.; and Johnson & Johnson. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the market trends in each of the sub-markets from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the GERD therapeutics market on the basis of drug type and region:
Drug Type Outlook (Revenue, USD Million; 2014 - 2025)
Antacids
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
Pro-kinetic agents
Regional Outlook (Revenue, USD Million; 2014 - 2025)
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
Japan
China
Latin America
Brazil
MEA
South Africa
b. The global gastroesophageal reflux disease therapeutics market size was estimated at USD 4.8 billion in 2019 and is expected to reach USD 4.6 billion in 2020.
b. The global gastroesophageal reflux disease therapeutics market is expected to decline at a compound annual growth rate of 2.3% from 2019 to 2025 to reach USD 4.4 billion by 2025.
b. North America dominated the gastroesophageal reflux disease therapeutics market with a share of 28.9% in 2019. This is attributable to high incidence of GERD for instance in the U.S., every year, more than 80 million people experience GERD symptoms, of which, 25 million people suffer from heartburn or acid reflux daily and 60 million people on a monthly basis.
b. Some key players operating in the gastroesophageal reflux disease therapeutics market include AstraZeneca PLC; Eisai Co., Ltd.; GlaxoSmithKline PLC; Takeda Pharmaceutical Co., Ltd.; and Johnson & Johnson.
b. Key factors that are depriving the market growth include patent expiry of blockbuster drugs prescribed.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.